Chinese expert consensus on the clinical diagnosis and treatment of autosomal dominant optic atrophy (2024)

Zhonghua Yan Ke Za Zhi. 2024 Mar 11;60(3):226-233. doi: 10.3760/cma.j.cn112142-20231225-00308.

ABSTRACT

Autosomal dominant optic atrophy (ADOA) primarily affects retinal ganglion cells and their axons, resulting in varying degrees of central vision loss from childhood. Due to the rarity of ADOA in clinical practice, Chinese ophthalmologists currently lack sufficient understanding of the disease and experience non-standardized diagnostic procedures and high clinical and genetic misdiagnosis rates. To address these issues, the Ophthalmology Group of China Alliance for Rare Diseases/Beijing Society of Rare Disease Clinical Care and Accessibility and the Neuro-ophthalmology Group of Ophthalmology Branch of Chinese Medical Association have established an expert panel to form consensus opinions based on extensive discussions. This consensus would enhance the knowledge and diagnostic capabilities of Chinese clinicians regarding ADOA and promote awareness of related treatment principles and genetic counseling.

PMID:38462370 | DOI:10.3760/cma.j.cn112142-20231225-00308